Non intervention registration of pabolizumab in preoperative neoadjuvant therapy for advanced esophageal cancer

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100053631

Enrollment

Unknown

Registered

2021-11-26

Start date

2022-01-01

Completion date

Unknown

Last updated

2023-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal cancer

Interventions

Pabolizumab group:None

Non-pabolizumab group:None

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Aged >= 18 years; 2.Sign informed consent and voluntarily join the study; 3.Patients with histologically or cytologically confirmed advanced esophageal cancer (esophageal or esophagogastric junction cancer) (AJCC 8th Edition); 4.The investigator determined that the patient could be treated with pabolizumab.

Exclusion criteria

Exclusion criteria: 1.There is evidence that the patient is a pregnant or lactating woman; 2.The patient is receiving the treatment scheme of blind test; 3.The researcher judges other situations that are not suitable for inclusion in the study.

Design outcomes

Primary

Measure	Time frame
Physical condition score;Adverse event;	—

Secondary

Measure	Time frame
Overall survival;Progression free survival;Objective response rate;Disease control rate;Time of treatment failure;	—

Countries

China

Contacts

Public ContactZhou Wei

The First Affiliated Hospital of Air Force Medical University

zhouwei1@fmmu.edu.cn+86 13720542643

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026